For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor ...

But patients taking GLP-1 drugs did have a greater likelihood of retained gastric contents and of aborted upper endoscopies, ...

Recent studies have shown that pharmacological treatment with GLP-1-RA and dual GLP-1/glucose-dependent insulinotropic ...

GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or ...

Today, leading global communications network Havas hosts its inaugural "GLP101 Day" conference to showcase a holistic view of GLP-1 drugs and explore the significant disruptions brought on by their ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new recommendations.

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

The use of glucagon-like peptide 1 (GLP-1) agonists in patients with inflammatory bowel disease (IBD) was associated with few ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective ...

The warning affects all treatments containing GLP-1 receptor agonists, including semaglutide ( Ozempic, Wegovy, Rybelsus ), ...